Quest Diagnostics (DGX) EBT (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of EBT data on file, last reported at $334.0 million in Q1 2026.

• Quarterly EBT rose 21.01% year-over-year to $334.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 16.12% YoY) and the FY2025 annual result came in at $1.3 billion, up 12.17% from the prior year.
• EBT grew to $334.0 million in Q1 2026 per DGX's latest filing, from $330.0 million in the prior quarter.
• The five-year high for EBT was $452.0 million in Q1 2022, with the low at $109.0 million in Q4 2022.
• Average EBT over 5 years is $305.4 million, with a median of $314.0 million recorded in 2024.
• Year-over-year, EBT slumped 78.29% in 2022 and jumped 117.43% in 2023.
• Quest Diagnostics' EBT stood at $109.0 million in 2022, then jumped by 117.43% to $237.0 million in 2023, then rose by 26.16% to $299.0 million in 2024, then increased by 10.37% to $330.0 million in 2025, then grew by 1.21% to $334.0 million in 2026.
• Business Quant data shows DGX's EBT at $334.0 million in Q1 2026, $330.0 million in Q4 2025, and $328.0 million in Q3 2025.